PPARG and metabolic dysfunction-associated steatohepatitis: Several evidences support that the PPAR-γ agonist pioglitazone effectively alleviates liver fibrosis caused by NASH, and is recommended for the treatment of NASH (Harrison et al., 2023d; Cusi et al., 2016).